
Product Data Sheet

Product Name: AP-III-a4 hydrochloride

Cat. No.: GC35371

Chemical Properties

Cas. No. 2070014-95-6

SMILES FC1=CC=C(CNC2=NC(NCC3CCCCC3)=NC(NC4=CC=C(CC(NCCOCCOCCN)=O)C=C4)=N2)C=C1.ClFormula $C_{31}H_{44}ClFN_8O_3$

M.Wt

631.18

Solubility DMSO: ≥ 53 mg/mL (83.97 mM)

Storage

Store at $-20^{\circ}C$

General For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic tips bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice Condition upon request.

Structure **Protocol****Cell experiment [1]:**

Cell lines NCI-H929 cells

Preparation Method NCI-H929 cells were cultured in RPMI-1640 or Dulbecco's modified Eagle's medium at $37^{\circ}C$ in a humidified atmosphere with 5% CO_2 . NCI-H929 cells were treated with 0.2-1.6 μM AP-III-a4 hydrochloride for 72 hours.

Reaction Conditions 0.2-1.6 μM ; 72h

Applications AP-III-a4 hydrochloride inhibits the proliferation of cancer cells.

Animal experiment [1]:

Animal models Multiple myeloma (MM) xenograft model

Preparation Method BALB/c nude mice were used for the xenograft experiments. The mice were randomly assigned to four groups: vehicle control group, bortezomib (BTZ) treatment group (1mg/kg), ENO1 inhibitor (AP-III-a4 hydrochloride) treatment group (10mg/kg), and combination treatment group (BTZ + AP-III-a4). AP-III-a4 and BTZ were administered via intraperitoneal injection every two days. Tumor volume and body weight were monitored regularly throughout the treatment period.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Dosage form 10mg/kg; ip; 15d

Applications In MM xenograft model, the combination of AP-III-a4 hydrochloride and BTZ has a more significant growth inhibitory effect in vivo than AP-III-a4 hydrochloride or BTZ alone.

References:

[1]. Gao X, Feng Q, Zhang Q, et al. Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis. Journal of Biomedical Science. 2025 Jan 20; 32(1): 9.

Background

AP-III-a4 hydrochloride is the first non-substrate analog inhibitor of enolase ($IC_{50} = 0.576\mu M$) [1]. AP-III-a4 hydrochloride induces cell death under hypoxia and inhibits cancer cell migration and invasion by downregulating AKT and Bcl-xL expression [1]. AP-III-a4 hydrochloride is often used in cancer research [2-3].

In HCT116 cells, AP-III-a4 hydrochloride (10 μM , 24h) induced cell death under hypoxia and inhibited cancer cell migration and invasion by downregulating AKT and Bcl-xL expressions [1]. In NCI-H929 cells, AP-III-a4 hydrochloride (0.2-1.6 μM ; 72h) inhibits the proliferation of cancer cells [4]. In H9c2 cells, AP-III-a4 hydrochloride (10 μM , 24h) inhibitor group displayed markedly reduced glucose and lactate levels [5].

In the Multiple myeloma (MM) xenograft model, the combination of AP-III-a4 hydrochloride (10mg/kg; ip; 15d) and BTZ has a more significant growth inhibitory effect in vivo than AP-III-a4 hydrochloride or BTZ alone [4].

References:

- [1]. Jung DW, Kim WH, Park SH, et al. A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes. ACS chemical biology. 2013 Jun 21; 8(6): 1271-1282.
- [2]. Chen X, Xu H, Wu N, et al. Interaction between granulin A and enolase 1 attenuates the migration and invasion of human hepatoma cells. Oncotarget. 2017 Mar 17; 8(18): 30305.
- [3]. Wang C, Huang M, Lin Y, et al. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nature Metabolism. 2023 Oct; 5(10): 1765-1786.
- [4]. Gao X, Feng Q, Zhang Q, et al. Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis. Journal of Biomedical Science. 2025 Jan 20; 32(1): 9.
- [5]. Guo Z, Liu S, Hou X, et al. Isorhamnetin Attenuates Isoproterenol-Induced Myocardial Injury by Reducing

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

ENO1 (Alpha-Enolase) in Cardiomyocytes. Antioxidants. 2025 May 11; 14(5): 579.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA